The clinical relevance of the RB1/E2F3a onco-spliceosome signature (REOSS) was demonstrated across various cancer types, with elevated expression observed in tumors exhibiting low RB1 and high E2F3a expression levels, which also correlated with poor prognosis in osteosarcoma (OS) patients. This evidence concerns the gene RB1 and cancer.